Detailed Narrative
Q4 FY26 Financial Performance Overview
Dhanuka Agritech delivered resilient operational and financial performance in Q4 FY26. Revenue from operations stood at ₹483.34 crores, marking a growth of approximately 9.35% compared to ₹442.02 crores in Q4 FY25. Profit after tax significantly improved to ₹97.77 crores from ₹75.50 crores in the corresponding quarter of the previous year, reflecting healthy profitability driven by product mix and cost management. EBITDA for the quarter was ₹124.89 crores, with an EBITDA margin of 25.84%.
Shareholder Returns and Employee Incentives
The Board of Directors recommended a 100% dividend, equivalent to ₹2 per equity share, which will absorb approximately ₹9.02 crores. A share buyback proposal was also approved for up to ₹70 crores, at a maximum price of ₹1,400 per share, demonstrating confidence in the company's long-term value. Additionally, an Employee Stock Option Plan (ESOP) scheme was introduced to foster an entrepreneurial mindset and align employee interests with the company's growth.
Challenging Operating Environment and Outlook
The agrochemical industry faced a challenging operating environment in Q4 FY26, characterized by erratic weather patterns, uneven crop economics, weak channel liquidity, and global supply chain uncertainties. The Rabi season was particularly impacted by unfavorable climatic conditions. Despite these near-term headwinds, management remains constructive on the medium-to-long-term structural growth opportunities for Indian agriculture and crop production.
Impact of GST Refund on Margins
The significant expansion in EBITDA margin during Q4 FY26 was largely attributed to a GST refund of ₹14.5 crores in the quarter, contributing to a total of ₹29 crores for the full FY26. For FY27, the company anticipates a 100 bps decline in EBITDA margin due to the absence of this GST refund benefit and some reduction in net economic benefit. However, management expects to maintain gross margins at 25-26% for the upcoming financial year.
New Product Performance and Dahej Unit Update
The acquired Bayer products, Triadimenol and Iprovalicarb, are seeing continued commercialization, with Melody Duo (India sales) contributing ₹27 crores in FY26. The company expects this to double in FY27 and reach ₹200 crores by FY28. The Dahej manufacturing unit recorded sales of ₹50 crores in FY26 (up from ₹41 crores in FY25) but incurred a loss of ₹13 crores. The biostimulant portfolio, which saw revenue decline to ₹70 crores in FY26 from ₹110 crores in FY25 due to regulatory changes, is targeted to exceed ₹130 crores in FY27 with new product launches.
Kharif Season Outlook & Input Cost Management
Management expressed optimism for the upcoming Kharif season, particularly Q1 FY27, citing good rainfall forecasts and a strong weedicide portfolio. Overall input prices have increased by 5-7% due to global volatility🌐. The company expects to pass on approximately 2% of this increase in Q1 and an additional 3-4% in Q2, leveraging its carryover inventory to mitigate the immediate impact of rising costs.
International Expansion and Alliance Status
Dhanuka Agritech is actively pursuing international expansion, having appointed customers in five countries and in advanced discussions with ten more. However, challenges persist at the distributor level in overseas markets, primarily related to achieving desired sales volumes and maintaining pricing. The previously announced alliance with a Spanish company for biological products was called off due to identified 'red flags' in the Memorandum of Understanding.